Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Rating)’s share price was up 1.2% during trading on Friday . The company traded as high as $63.27 and last traded at $63.27. Approximately 1,235 shares changed hands during trading, a decline of 99% from the average daily volume of 229,736 shares. The stock had previously closed at $62.49.
Analysts Set New Price Targets
Separately, B. Riley downgraded Madrigal Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $131.00 to $75.00 in a research report on Friday, July 8th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Madrigal Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $161.00.
Madrigal Pharmaceuticals Price Performance
The stock has a fifty day moving average of $69.48 and a 200-day moving average of $75.19. The company has a quick ratio of 2.55, a current ratio of 2.55 and a debt-to-equity ratio of 0.58. The stock has a market capitalization of $1.08 billion, a price-to-earnings ratio of -4.15 and a beta of 1.00.
Hedge Funds Weigh In On Madrigal Pharmaceuticals
Madrigal Pharmaceuticals Company Profile
Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis.
- Get a free copy of the StockNews.com research report on Madrigal Pharmaceuticals (MDGL)
- Why Does Tesla Stock Remain Resilient?
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
- Is Costco’s Post-Earnings Price Weakness A Good Time To Buy?
- 2 Semiconductor Stocks To Watch For Reversals
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.